
The economy is becoming sustainable – and the stock market is delighted: dynaCERT, Siemens, Shell
ESG criteria have become established across all industries. The prevailing principle in today's business world is that even producers of fossil energy must take action to become more sustainable. This principle is known as 'Best-in-Class' and ensures that every industry makes the most of its opportunities to move toward greater sustainability. We present three exciting sustainable business models – Shell, Siemens, and dynaCERT – and explain where opportunities may lie for investors. Even Shell aims to become climate-neutral
It has been clear for many years that oil company Shell needs a sustainability strategy. More than ten years ago, Shell was a prime example of the risks associated with oil production. The accident on an oil platform kept the media in suspense. Shell was considered severely damaged – billions in compensation payments were in the air. And today? Shell is pursuing its 'Performance, Discipline, Simplification' strategy and is focusing more on LNG growth while investing in low-carbon energy solutions. The Company plans to increase LNG revenue by 4 to 5% annually by 2030, while oil production is to remain stable at 1.4 million barrels per day. Between 2023 and 2025 alone, the energy company invested USD 10 to 15 billion in low-carbon energy solutions. A flagship project is Holland Hydrogen I, Europe's largest renewable hydrogen plant with a capacity of 200 MW, which is expected to produce 60,000 kg of green hydrogen per day. Shell aims to become climate-neutral by 2050. dynaCERT: Transition technology for heavy machinery
Canadian company dynaCERT (TSX:DYA) also aims to benefit from the shift of many traditional industrial companies toward hydrogen. The pioneers of conversion kits for diesel engines have long identified heavy machinery as a key growth market. dynaCERT owns the patented HydraGEN™ technology, which uses small injections of hydrogen into the combustion process of diesel engines to reduce diesel consumption and, at the same time, pollutant and greenhouse gas emissions. Using their telematics solution, HydraLytica™, companies can even document their savings and convert them into CO2 certificates. dynaCERT has been certified under Verra's Carbon Credit Methodology.**
There are still millions of vehicles and machines powered by diesel. Especially in times when investments are difficult, dynaCERT's transition technology can leverage ESG potential and give proven machines and vehicles a longer service life. Heavy machinery, in particular, which has often been integrated into operational processes for many years and proven its reliability, can be operated longer thanks to dynaCERT. In recent years, the Company has increasingly reached out to industrial clients. dynaCERT even established a branch in Germany and is now competing for customers there. The analysts at GBC have issued a 'Buy' recommendation for the stock, with an ambitious price target of CAD 0.75. GBC forecasts revenues of CAD 21 million for 2025, representing significant growth. For 2026, they expect an operating result (EBITDA) of CAD 4.79 million. If this happens, it would mark a turning point for the Company, which has been working toward this breakthrough for some time. Siemens: Digitalization and sustainability
Siemens proves that it can be well worth building bridges between old and new industries through innovative technology and digitalization. A central component of its strategy for the future is industrial AI. At Automate 2025, Siemens announced an expansion of its Industrial AI offerings with advanced AI agents that are expected to enable productivity increases of up to 50% for industrial companies. Sustainability will not be neglected in this development – the Company has set itself the goal of becoming climate-neutral by 2030. In the second quarter of fiscal 2025, Siemens achieved strong results: Revenue rose by 3% to EUR 18.4 billion, while order intake increased significantly. The Smart Infrastructure business segment, which is important for the Company's ESG requirements, is expected to grow between 6% and 9% in fiscal 2025. When could this stock surprise?
The Siemens share climbed by 14.2% in the last six months and could show renewed momentum beyond the EUR 220 mark. Shell shares, on the other hand, have suffered a setback – the temporary ceasefire in the Middle East has abruptly halted the upward momentum of the shares. Shell's sustainability fantasy has not yet had an impact on the share price. The situation is similar for growth stock dynaCERT, whose share price has lost around 25% over the past six months. However, given its small market capitalization of just around EUR 40 million, a surprise is always in the air with dynaCERT: should major orders or a comprehensive partnership with an industrial company materialize, the stock will likely face a revaluation. Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as 'Relevant Persons') may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a 'Transaction'). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies. Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.
The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.
This is sponsored content issued on behalf of Apaton Finance GmbH, please see full disclaimer here.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Cision Canada
27 minutes ago
- Cision Canada
Acclaro Medical Receives Health Canada Approval for UltraClear® 2910 nm Cold Ablative Fiber Laser
~ Groundbreaking Laser Featuring Superficial 3DMIRACL ® and First-of-its-Kind Laser Coring ™ ~ Acclaro Medical Partners with Xcite Technology, North America's Leading Provider of Revolutionary Energy-Based Skin Technologies, to Drive Canadian Distribution Efforts SMITHFIELD, R.I., June 25, 2025 /CNW/ -- Acclaro Medical, a global innovator in advanced energy-based technologies for aesthetic, ophthalmic and surgical markets, is proud to announce the approval of its flagship UltraClear ® 2910 nm fiber laser by Health Canada. This clearance marks a significant expansion for the company and brings one of the industry's most advanced skin rejuvenation platforms to Canadian provider and patients. Acclaro Medical has also partnered with Xcite Technology, a recognized leader in aesthetic energy-based device distribution, to spearhead commercialization efforts across Canada. Engineered with proprietary MID IR Fiber Laser and 3DIntelliPulse™ technology, UltraClear is the world's first and only 2910 nm cold ablative fiber offering precise, customizable treatments that address superficial to deep skin concerns with minimal downtime and exceptional patient comfort. Its unique treatment modes, including 3DMIRACL ® for gentle resurfacing and Laser Coring™ to help reverse a wide range of telltale signs associated with aging and gravity, set a new standard for what's possible in total skin health. "The approval of our UltraClear in Canada as the first and only 2910 nm fiber laser marks a significant milestone in our steadfast commitment to bringing breakthrough innovation to Canadian aesthetic providers and their patients," said Helen Fang, CEO, Acclaro Medical. "Across Acclaro Medical, we are proud of our shared vision to deliver category-defining solutions for a full range of patient-friendly treatment options tailored to their needs, lifestyles and skin types." As the exclusive Canadian distributor, Xcite Technologies will bring UltraClear to aesthetic clinics nationwide. With a strong track record in introducing disruptive technologies to the market, Xcite is ideally positioned to support clinical adoption and elevate standards in laser-based treatments. "UltraClear is unlike anything currently available," said Bill Roberts, CEO of Xcite Technologies. "The 2910 nm cold ablative fiber laser combined with proprietary Laser Coring technology delivers a level of precision, depth, and patient comfort that truly redefines what's possible in skin rejuvenation. This is a major step forward for Canadian providers looking to offer high-efficacy treatments with minimal downtime and broad patient appeal." About Acclaro Medical Founded in 2018 by world-class industry experts, Acclaro Medical is committed to developing, innovating and bringing to market game-changing solutions to address today's unmet medical, aesthetic and surgical practice needs. With a relentless commitment to innovation and a team of dedicated professionals, Acclaro Medical continues to push the boundaries and drive positive change in the aesthetic medical industry. Its proprietary 3DMIRACL ® and Laser Coring ® skin rejuvenation treatments are valued for offering unrivaled aesthetic results complemented by high patient comfort, rapid healing and utmost safety across all skin types. For more information, please visit or contact Xcite Technologies for regional availability. Xcite Technologies is Canada's leading distributor of advanced medical aesthetic technologies, known for bringing the most innovative, clinically proven aesthetic solutions. With a consistent track record of launching state-of-the-art platforms like UltraClear, Xcite remains at the forefront of aesthetic medicine—ensuring Canadian providers have access to the latest global advancements in energy-based treatments that address the full spectrum of skin types and concerns.


Cision Canada
an hour ago
- Cision Canada
Grand Challenges Canada to Anchor Gavi's Innovation Fund to Scale Immunization Solutions Français
New strategic partnership will accelerate the scale-up of high-impact immunization delivery innovations BRUSSELS, June 25, 2025 /CNW/ - Grand Challenges Canada (GCC), one of the world's leading impact-first investors, is proud to announce a strategic partnership with Gavi, the Vaccine Alliance, to scale proven innovations that advance equitable access to immunization and strengthen health systems in low- and middle-income countries (LMICs). As part of this collaboration, GCC will anchor Gavi's Innovation Scale-Up Fund with an initial pledge of $10 million CAD, with the potential to contribute up to $30 million CAD in additional investment, subject to the closing and final structure and size of the Fund. This transformative partnership aims to accelerate the scale-up of high-impact innovations in immunization delivery, resulting in significant improvements in health system efficiency, health outcomes, and sustainability. This new partnership builds on Canada's long-standing support for Gavi and reinforces GCC's perspective to advance global health equity through innovation and collaboration. As part of this collaboration, Grand Challenges Canada will draw on its extensive pipeline of more than 1,500 innovations in more than 100 countries, alongside deep expertise in blended finance and scaling locally led solutions. Gavi brings deep experience in innovative financing, demand generation, and strong partnerships with national governments. "We are proud to join forces with Gavi to help scale the most promising innovations in immunization delivery. As Canada's innovation platform, Grand Challenges Canada brings 15 years of experience identifying, de-risking, and scaling bold ideas that improve lives. Together, we can close immunization gaps and strengthen health systems where the need is greatest," said Dr. Karlee Silver, CEO of Grand Challenges Canada The partnership reflects a shared belief that innovation—when responsibly scaled—can transform lives and strengthen health systems. Over the coming months, GCC and Gavi will work together to finalize the Fund's structure and mobilize additional resources. The Fund will launch upon securing commitments of at least $50 million USD, with an overall target of $300 million USD. "Scaling innovation is essential to closing the immunisation gap and ensuring that no one is left behind. This partnership with Grand Challenges Canada brings vital expertise and catalytic capital to help proven delivery solutions reach more communities, faster than ever before." Said Dr Sania Nishtar, CEO of Gavi, the Vaccine Alliance. "Together, we can accelerate progress towards stronger, more equitable health systems." Since 2010, Grand Challenges Canada has been one of the world's leading impact-first investors, using various sources and types of capital to support innovators improving health outcomes, advancing gender equality, and building more resilient systems. Notes to Editors About Grand Challenges Canada Grand Challenges Canada backs Bold Ideas with Big Impact®. As one of the world's leading impact-first investors and a global innovation platform, we envision a world where innovation helps everyone thrive. We identify, invest in, and help scale solutions that improve lives in underserved communities across low- and middle-income countries and Canada. From seed to scale, we provide flexible support to help innovators grow, adapt and succeed. Since 2010, we've supported over 1500 unique innovations in more than 100 countries, reaching over 85 million people. By 2035, we aim to reach 750 million. Learn more at About Gavi, the Vaccine Alliance Gavi, the Vaccine Alliance is a public-private partnership that helps vaccinate more than half the world's children against some of the world's deadliest diseases. The Vaccine Alliance brings together developing country and donor governments, the World Health Organization, UNICEF, the World Bank, the vaccine industry, technical agencies, civil society, the Gates Foundation and other private sector partners. View the full list of donor governments and other leading organisations that fund Gavi's work here. Since its inception in 2000, Gavi has helped to immunise a whole generation – over 1.1 billion children – and prevented more than 18.8 million future deaths, helping to halve child mortality in 78 lower–income countries. Gavi also plays a key role in improving global health security by supporting health systems as well as funding global stockpiles for Ebola, cholera, meningococcal and yellow fever vaccines. After two decades of progress, Gavi is now focused on protecting the next generation, above all the zero-dose children who have not received even a single vaccine shot. The Vaccine Alliance employs innovative finance and the latest technology – from drones to biometrics – to save lives, prevent outbreaks before they can spread and help countries on the road to self-sufficiency. Learn more at


Cision Canada
an hour ago
- Cision Canada
Canada Life Reinsurance strengthens focus on structured reinsurance; ceases new business for U.S. traditional mortality risk reinsurance Français
BLUE BELL, Pa., June 25, 2025 /CNW/ - Today, Canada Life Reinsurance, a wholly owned subsidiary of Great-West Lifeco Inc. (TSX: GWO) ("Lifeco") announced some changes to its business strategy. Canada Life Reinsurance will cease new business for its US traditional life mortality risk reinsurance line of business ("U.S. Trad Life"). A key motivation behind this decision is increasing the resources devoted to the structured reinsurance market. Canada Life Reinsurance will continue to focus on providing capital and reserve financing solutions for companies in a wide variety of product lines and geographic locations. For current US Trad Life clients with treaties open for new business, the company will provide notices to terminate new business effective December 31, 2025. The company will work closely with existing clients to provide a smooth transition process for both facultative and automatic new business. Canada Life Reinsurance will continue to manage, process and support all inforce business and clients. "This carefully considered decision will allow Canada Life Reinsurance to focus on our core markets of structured solutions, longevity reinsurance and Catastrophe retrocession," said Jeff Poulin, Executive Vice-President, Reinsurance. "With a large U.S. Trad Life inforce block to manage, our clients will be expecting the same high levels of service that we have been providing. We remain committed to meeting our clients' expectations." About Canada Life Reinsurance Canada Life Reinsurance offers a range of innovative risk and capital management solutions. Operating primarily in the U.S., Barbados, Bermuda and Ireland, the company provides reinsurance to other reinsurers to allow those companies to manage their reinsurance risk. The product portfolio offered includes life, annuity/longevity, mortgage surety and property catastrophe reinsurance, provided on both a proportional and non-proportional basis. Canada Life Reinsurance is a division of The Canada Life Assurance Company and certain of its subsidiaries and affiliates. The Canada Life Assurance Company is a subsidiary of Great-West Lifeco Inc. and a member of the Power Financial Corporation group of companies. About Great-West Lifeco Inc. Great-West Lifeco is a financial services holding company focused on building stronger, more inclusive and financially secure futures. We operate in Canada, the United States and Europe under the brands Canada Life, Empower and Irish Life. Together we provide wealth, retirement, workplace benefits and insurance and risk solutions to over 40 million existing customer relationships. As of December 31, 2024, Great-West Lifeco's total client assets exceeded $3 trillion. Great-West Lifeco trades on the Toronto Stock Exchange (TSX) under the ticker symbol GWO and is a member of the Power Corporation group of companies. To learn more, visit